NCI-H524Homo sapiens (Human)Cancer cell line

Also known as: NCIH524, H-524, H524

🤖 AI SummaryBased on 12 publications

Quick Overview

Small cell lung cancer cell line with known genetic alterations

Detailed Summary

NCI-H524 is a small cell lung cancer (SCLC) cell line derived from a human tumor. It is widely used in cancer research due to its specific genetic characteristics. This cell line has been studied for its response to various therapeutic agents, including PARP inhibitors and Bcl-2 antagonists. Research has shown that NCI-H524 exhibits specific protein expression profiles and genetic mutations that make it a valuable model for studying SCLC biology and drug sensitivity. It is particularly noted for its sensitivity to certain targeted therapies, making it a key tool in developing personalized cancer treatments.

Research Applications

Drug sensitivity testingGenetic mutation analysisProtein expression profilingTherapeutic target identification

Key Characteristics

Sensitivity to PARP inhibitorsBcl-2 antagonist sensitivitySpecific genetic alterations in SCLCProtein expression profiles associated with SCLC
Generated on 6/17/2025

Basic Information

Database IDCVCL_1568
SpeciesHomo sapiens (Human)
Tissue SourceLymph node[UBERON:UBERON_0000029]

Donor Information

Age63
Age CategoryAdult
SexMale
Racecaucasian

Disease Information

DiseaseSmall cell lung cancer
LineageLung
SubtypeSmall Cell Lung Cancer
OncoTree CodeSCLC

DepMap Information

Source TypeATCC
Source IDACH-000816_source

Known Sequence Variations

TypeGene/ProteinDescriptionZygosityNoteSource
MutationSimpleTP53p.Thr155Asn (c.464C>A)Unspecified-from parent cell line UW228
MutationSimpleRB1p.Ser576Ter (c.1727C>G)Homozygous-from parent cell line Hep 3B2.1-7
MutationSimpleATMp.Arg337Cys (c.1009C>T)Heterozygous-Unknown, Unknown

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin
X
CSF1PO
12
D13S317
12
D16S539
12
D18S51
12,13
D19S433
16
D21S11
29,30
D2S1338
16,17
D3S1358
15
D5S818
12
D7S820
11,12
D8S1179
13,15
FGA
21,22,25
Penta D
12,13
Penta E
5,15
TH01
8,9.3
TPOX
8,10
vWA
14,17
Gene Expression Profile
Gene expression levels and statistical distribution
Loading cohorts...
Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Pan-cancer proteomic map of 949 human cell lines.";

Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.

Cancer Cell 40:835-849.e8(2022).

From clinical specimens to human cancer preclinical models -- a journey the NCI-cell line database-25 years later.

Aldige C.R., Wistuba I.I., Minna J.D.

J. Cell. Biochem. 121:3986-3999(2020).

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Sellers W.R.

Nature 569:503-508(2019).

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

LMO1 functions as an oncogene by regulating TTK expression and correlates with neuroendocrine differentiation of lung cancer.

Minna J.D., Wistuba I.I., Pertsemlidis A.

Oncotarget 9:29601-29618(2018).

Characterization of human cancer cell lines by reverse-phase protein arrays.

Liang H.

Cancer Cell 31:225-239(2017).

A landscape of pharmacogenomic interactions in cancer.";

Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

Cell 166:740-754(2016).

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Loewer M., Sahin U., Castle J.C.

Genome Med. 7:118.1-118.7(2015).

Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies.

Golub T.R., Root D.E., Hahn W.C.

Sci. Data 1:140035-140035(2014).

A resource for cell line authentication, annotation and quality control.

Neve R.M.

Nature 520:307-311(2015).

Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1.

Heymach J.V.

Cancer Discov. 2:798-811(2012).

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

Nature 483:603-607(2012).

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Haber D.A.

Cancer Res. 70:2158-2164(2010).

Signatures of mutation and selection in the cancer genome.";

Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Nature 463:893-898(2010).

Integrative genomic analysis of small-cell lung carcinoma reveals correlates of sensitivity to bcl-2 antagonists and uncovers novel chromosomal gains.

Sauter G., Lesniewski R., Semizarov D.

Mol. Cancer Res. 5:331-339(2007).

Protein expression of the RB-related gene family and SV40 large T antigen in mesothelioma and lung cancer.

Modi S., Kubo A., Oie H.K., Coxon A.B., Rehmatulla A., Kaye F.J.

Oncogene 19:4632-4639(2000).

MYC family DNA amplification in 126 tumor cell lines from patients with small cell lung cancer.

Ihde D.C., Gazdar A.F.

J. Cell. Biochem. Suppl. 24:210-217(1996).

NCI-Navy Medical Oncology Branch cell line data base.";

Carney D.N., Minna J.D., Mulshine J.L.

J. Cell. Biochem. Suppl. 24:32-91(1996).

Subcellular localization and supramolecular organization of neuroendocrine-specific protein B (NSP-B) in small cell lung cancer.

Kuijpers H.J.H., Roebroek A.J.M., van de Ven W.J.M., Ramaekers F.C.S.

Eur. J. Cell Biol. 65:341-353(1994).

Analysis of human small cell lung cancer differentiation antigens using a panel of rat monoclonal antibodies.

Gazdar A.F., Minna J.D.

Cancer Res. 44:2052-2061(1984).

Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay.

Fine D.L., Abbott B.J., Mayo J.G., Shoemaker R.H., Boyd M.R.

Cancer Res. 48:589-601(1988).

Characterization of variant subclasses of cell lines derived from small cell lung cancer having distinctive biochemical, morphological, and growth properties.

Gazdar A.F., Carney D.N., Nau M.M., Minna J.D.

Cancer Res. 45:2924-2930(1985).

Establishment and identification of small cell lung cancer cell lines having classic and variant features.

Moody T.W., Zweig M.H., Minna J.D.

Cancer Res. 45:2913-2923(1985).

Spontaneous changes in intermediate filament protein expression patterns in lung cancer cell lines.

Carney D.N., Vooijs G.P., Ramaekers F.C.S.

J. Cell Sci. 91:91-108(1988).

Metabolic activation of 4-ipomeanol in human lung, primary pulmonary carcinomas, and established human pulmonary carcinoma cell lines.

Adelberg S., Czerwinski M.J., McMahon N.A., Eggleston J.C., Boyd M.R.

J. Natl. Cancer Inst. 82:1420-1426(1990).

Novel antigens characteristic of neuroendocrine malignancies.";

Boerman O.C., Ramaekers F.C.S.

Cancer 67:619-633(1991).

Expression of the vasopressin and gastrin-releasing peptide genes in small cell lung carcinoma cell lines.

Burbach J.P.H.

Pathobiology 60:136-142(1992).

Web Resources